Phase 2 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a psoriasis severity score (called a PASI score) of less than 10, meaning their psoriasis is considered mild
- People who have been fully informed about the study and have agreed to take part by signing a consent form
- People aged between 18 and 60 years old who are in generally good health
- People who have not taken any medications in the past 6 months
- People who do not have any inflammatory or immune-related skin conditions, local skin infections, or nerve and muscle diseases
Who may not be able to join:
- People who have a type of psoriasis other than the type being studied, or who have severe psoriasis
- People whose skin condition is currently in an active flare, or who have other serious medical conditions
- People whom the researchers consider unsuitable for the trial — for example, those who may not be able to reliably follow or understand the study requirements (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 13873143466
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Transepidermal Water Loss(TEWL); General appearance photography; Dermoscopic photography; Completion of self-assessment questionnaires; Adverse reactions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.